Glenmark Generics Limited

Other

Mubeen Ahmed Khan

Sukumar Sinha

Nikhil Rasiklal Trivedi

Nitin Sharad Chandra Pradhan

Mangesh Shivram Sawant

Sharad R Gore

Shankar Sanganabhatla

Sankar Arjunan

Navin Ganesh Bhatt

Nagan Nirmalan Kandasamy

Dayaghan Gangadhar Patil

Vipin Kumar Pandey

Mahesh Khedekar

Ramjilal Yadav

Vijay Soni

Nandlal Agarwal

Hemanth Kamble

Mahendra Raghunath Patil

Maloyesh Mathuresh Biswas

Nikhil Rasiklaltrivedi

Navin Ganeshbhatt

A solid crystalline form of 1-(2-[4-(6-methoxy-3,4-dihydronaphthalene-1-y) phenoxy]ethyl)pyrrolidine, and a preparing process thereof are provided. The aforesaid compound is a key intermediate in the synthesis of lasofoxifene. A process for preparing lasofoxifene, a process for purifying lasofoxifene tartrate, and a crystalline form of lasofoxifene tartrate are also provided.

Process for the preparation of lasofoxifene tartrate

The present invention generally relates to a process for the preparation of fosaprepitant dimeglumine intermediate and its use in the preparation of fosaprepitant dimeglumine; to a neutral form of fosaprepitant in a solid state and processes for the preparation thereof; and to a stable amorphous fosaprepitant dimeglumine, having a stability at temperatures of about 2&#xb0; C. to about 8&#xb0; C. and at a relative humidity below at least 60%; and a process for the preparation thereof.

Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations

The present invention provides an amorphous bupropion hydrobromide and an amorphous bupropion hydrobromide granulates with at least one pharmaceutically acceptable carrier, and a process for its preparation.

Amorphous bupropion hydrobromide and preparation thereof

The present invention provides processes for the preparation of R-sitagliptin (as shown) and its pharmaceutically acceptable salts thereof. 

Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof

Processes for the purification of lercanidipine hydrochloride are provided which uses a binary system of an alcohol-containing solvent such as methanol and an aliphatic ester-containing solvent such as isopropyl acetate. Processes for the preparation of substantially amorphous lercanidipine hydrochloride are also provided. Also provided is lercanidipine hydrochloride substantially in polymorph form V.

Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof

Growing community of inventors

Maharastra, India

Mubeen Ahmed Khan